Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
immunotherapy save search
BostonGene and Saga University Announce Collaboration to Uncover Biomarkers for Improved Immunotherapy Response in Lung Cancer Patients
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
NIPNF | $68.91 -7.25% -52.94% 0
|
Technology Services
| Email alert
Add to watchlist
lung cancer immunotherapy for collaboration saga response biomarkers
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
PVCT | News 4 | $0.195 2.63% -15.0% 56K
|
Manufacturing
|
| O: 0.0%
H: 17.21%
C: 7.19%
pv-10 presentation cancer immunotherapy for meeting
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
RAPT | $7.93 -1.37% -1.26% 630K
|
Health Technology
|
| O: 0.0%
H: 3.37%
C: 1.44%
cancer immunotherapy trial therapeutics results
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
CADL | $5.46 0.37% 0.91% 730K
|
|
| O: 3.99%
H: 4.32%
C: -18.56%
candidate tumors preclinical immunotherapy for therapeutics
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
BNTX | $86.17 -0.27% -0.24% 520K
|
Health Technology
|
| O: 1.38%
H: 0.2%
C: -1.27%
candidate cancer pancreatic tumor immunotherapy for response show
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
OCEA | $1.875 5.04% 4.55% 210K
|
|
| O: 0.49%
H: 0.0%
C: -7.23%
global immunotherapy
Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting
Published: 2024-03-28 (Crawled : 00:00) - prnewswire.com
OCEA | $1.875 5.04% 4.55% 210K
|
|
| O: 0.49%
H: 0.0%
C: -7.23%
vron-0200 hepatitis liver global immunotherapy meeting virus study
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
Published: 2024-03-21 (Crawled : 12:30) - globenewswire.com
LIXT | $3.351 0.63% 4.68% 18K
|
Health Technology
|
| O: -2.16%
H: 2.21%
C: 2.18%
lb-100 update cancer immunotherapy
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies—Poster will be unveiled this week at the Immunotherapy Conference in Munich
Published: 2024-03-21 (Crawled : 12:30) - biospace.com/
PHIO | $0.6378 -1.73% -3.02% 62K
|
Health Technology
|
| O: -4.67%
H: 0.43%
C: -17.65%
conference cell pharmaceuticals immunotherapy week therapy
World Cancer Immunotherapy Market Research 2023-2027: Curing Cancer is Generating Enormous New Opportunities - Outcome Potential, Technology Environment, Target Solutions
Published: 2024-03-16 (Crawled : 04:20) - prnewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
world cancer research solutions immunotherapy technology market
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
Published: 2024-03-12 (Crawled : 20:00) - prnewswire.com
PGEN | $1.32 0.76% 1.5% 950K
|
Health Technology
|
| O: 0.33%
H: 3.97%
C: 0.66%
prgn-2012 respiratory treatment immunotherapy
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: -1.36%
H: 4.48%
C: -4.14%
symposium cancer immunotherapy
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
Published: 2024-03-07 (Crawled : 13:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K
|
Professional, Scientific, and T...
|
| O: -0.64%
H: 4.52%
C: -6.45%
breast cancer
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
Published: 2024-03-07 (Crawled : 13:00) - globenewswire.com
PVCT | News 4 | $0.195 2.63% -15.0% 56K
|
Manufacturing
|
| O: 0.59%
H: 28.01%
C: 24.68%
pv-10 cancer immunotherapy meeting
Global Next Generation Immunotherapies Market 2023-2028: A $162.6 Billion Market by 2028, Registering CAGR of 7.6%
Published: 2024-02-02 (Crawled : 11:00) - prnewswire.com
AVTR | $24.3 -0.33% -0.29% 3.6M
|
Process Industries
|
| O: -0.59%
H: 0.9%
C: 0.0%
global market
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
Published: 2024-01-30 (Crawled : 13:00) - globenewswire.com
VAXX | $0.4648 11.2% 10.4% 440K
|
|
| O: 0.0%
H: 2.07%
C: -2.73%
active research collaboration neurodegenerative
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
LIXT | $3.351 0.63% 4.68% 18K
|
Health Technology
|
| O: 17.09%
H: 4.29%
C: -7.73%
lb-100 first cell immunotherapy trial
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
Published: 2024-01-25 (Crawled : 14:00) - globenewswire.com
ELTX | $8.23 -11.51% -15.24% 43K
|
|
| O: 1.52%
H: 19.1%
C: 14.93%
tumors publication cell preclinical therapeutics therapy
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
Published: 2024-01-22 (Crawled : 22:00) - globenewswire.com
TAK | News | $13.16 0.08% 0.53% 1.2M
|
Health Technology
|
| O: -0.14%
H: 0.17%
C: -0.27%
cabometyx asco immunotherapy trial
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
Published: 2024-01-16 (Crawled : 09:00) - biospace.com/
HALO M | $37.81 -0.55% -0.48% 550K
|
Health Technology
|
| O: -0.78%
H: 6.95%
C: 6.44%
tecentriq first approval cancer immunotherapy roche
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
UMAC | $1.55 0.65% 16.13% 3K
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
VLD 4 | $0.2638 -3.65% 13.27% 2.6M
|
Manufacturing
TAOP | $1.08 13.01% 11.51% 19K
|
Technology Services
MGLD 4 | $1.13 5.61% 10.62% 200
|
Manufacturing
NURO | $3.65 2.24% 10.3% 3.9K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.